Skip to content

The Impact of Remimazolam on the Incidence of Post-ECT Delirium in Patients with Psychiatric Disorders

The Impact of Remimazolam on the Incidence of Post-ECT Delirium in Patients with Psychiatric Disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099698
Enrollment
Unknown
Registered
2025-03-27
Start date
2025-03-31
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delirium

Interventions

Remimazolam group:Remimazolam anesthesia induction
propofol group:Propofol anesthesia induction

Sponsors

The Third Affiliated Hospital Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Patients who meet the indications for MECT (Modified Electroconvulsive Therapy) treatment; 2.Patients who voluntarily participate and sign an informed consent form; 3.Age 18–55 years; 4. ASA classification of I–II; 5.Patients with mental disorders such as depression, schizophrenia, and bipolar disorder, who are receiving MECT treatment for the first time or have an interval of 6 months since their last MECT treatment. 6.Patients of Han ethnicity; 7.Right-handed patients; 8.Patients with at least a middle school education who can cooperate well with the relevant examinations; 9.Patients without contraindications for magnetic resonance imaging and who can cooperate well with functional MRI.

Exclusion criteria

Exclusion criteria: 1. Patients with a recent history of infections or severe trauma such as fractures; 2.Severe impairment of heart, lung, liver, or kidney function; 3.History of allergy to propofol or remimazolam; 4.Participation in any clinical drug trials within the past 3 months; 5.Lactating women or pregnant women; 6.Presence of organic brain lesions, such as cerebral aneurysm or increased intracranial pressure; 7.Lack of a legal guardian; 8.Patients with cognitive or intellectual disabilities; 9.Patients who cannot cooperate to complete scale assessments.

Design outcomes

Primary

MeasureTime frame
post-ECT delirium,PECTD;

Secondary

MeasureTime frame
Changes in inflammatory markers;fMRI manifestations;Sedative Effects and Anesthesia Recovery;Seizure quality assessment;Cognitive function assessment;The status of clinical symptom relief;Hemodynamic changes and the incidence of adverse reactions.;Pre-treatment anxiety assessment;post-operative recovery quality;The patient's length of hospital stay and the total number of MECT sessions performed during the hospitalization.;

Countries

China

Contacts

Public ContactHei Ziqing

The Third Affiliated Hospital Sun Yat-sen University

heiziqing@sina.com+86 20 85253132

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026